PhaseBio Pharma Adds $15M in Series B Financing

5 years ago

PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.

Continue

EF Johnson Technologies Names Andrew Adams CEO

By Eamon — 5 years ago

EF Johnson Technologies Inc. named Andrew L. Adams chief executive offier. Adams replaced Norman Stout, who served in the role on an interim basis after the Irving, Texas-based company was bought by Francisco Partners in August. Stout remains chairman. Adams previously worked for Belden Corp. as president of the industrial solutions division.

Continue

Francisco Partners Completes EF Johnson Buyout

By PEHub Administrator — 6 years ago

Francisco Partners has completed its take-private acquisition of EF Johnson Technologies Inc. (Nasdaq: EFJI), an Irving, Texas-based provider of secure communications solutions to organizations that protect and save lives. The deal valued EF Johnson at nearly $40 million, or $1.50 per share.

Continue

Francisco Agrees To Pay More for EF Johnson

By PEHub Administrator — 6 years ago

Francisco Partners has amended the terms of its deal to acquire EF Johnson Technologies Inc. (Nasdaq: EFJI), an Irving, Texas-based provider of secure communications solutions to organizations that protect and save lives. The revised terms would pay out $1.50 per EF Johnson share, compared to an original purchase price of $1.05 per share. The total equity now would be valued at nearly $40 million.

Continue

Francisco Partners To Buy EF Johnson

By PEHub Administrator — 6 years ago

Francisco Partners has agreed to acquire EF Johnson Technologies Inc. (Nasdaq: EFJI), an Irving, Texas-based provider of secure communications solutions to organizations that protect and save lives. The deal is valued at around $27.8 million, or $1.05 per share.

Continue